A few years ago, Pfizer (PFE +0.51%) looked unstoppable. The company generated more than $100 billion in annual revenue early ...

Pfizer's new and recently acquired products generated 22% operational growth in Q1. The company faces a challenging road ...

Investors often move like lemmings in the short term, giving long-term investors an opportunity to buy great companies.

A legal settlement has put wind behind Pfizer’s sales into 2029—at which point key obesity moves will take the helm.

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...

Pfizer is looking to newer products and acquisitions to offset a declining Covid business.

Quick Read Eli Lilly (LLY) has shown revenue growth from a position of strength while Pfizer (PFE) is still rebuilding from ...

It looks like Pfizer Inc. ( NYSE:PFE ) is about to go ex-dividend in the next three days. The ex-dividend date is ...

Pfizer Inc. (NYSE:PFE) ranks among the best low-risk investments in May 2026. On April 13, Guggenheim reaffirmed a Buy rating ...

Pfizer’s first-quarter results gave investors a clearer view of how much work the drugmaker’s newer portfolio is doing as the ...

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle weakness and pain.